This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Alzheimer’s Disease: Translating Neurochemical Insights Into Clinical Benefits

Changiz Geula, Ph.D.; Martin Farlow, M.D.; Jeffrey Cummings, M.D.; John Morris, M.D.; Philip Scheltens, M.D., Ph.D.; and Ravi Anand, M.D.

Published: October 31, 2000

Article Abstract

Click to enlarge page

Dr. Changiz Geula reviewed recent evidence that updates the "cholinergic hypothesis" and provides insights into the clinical efficacy of cholinesterase (ChE) inhibitors. Alzheimer’s disease is widely acknowledged to involve characteristic morphologic brain lesions and neurochemical changes particularly within cortical cholinergic systems. Pathologic lesions in the brains of Alzheimer’s disease patients at postmortem consist of extracellular plaques formed primarily of the amyloid- protein and intraneuronal neurofibrillary tangles, stated Dr. Geula.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Dementia , Neurologic and Neurocognitive

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...